Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir plus 18α-glycyrrhizin to reverse cirrhosis in chronic hepatitis B
ChiCTR-IPR-16009493Phase 4Not yet recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Jan 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of entecavir and 18α-glycyrrhizin in Chronic Hepatitis B (CHB) and Cirrhosis (2 arms), sponsored by Shanghai Public Health Clinical Center. Primary endpoint: FibroScan value. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
entecavir18α-glycyrrhizin
03
Conditions
Chronic Hepatitis B (CHB)Cirrhosis
Beyond the preview
Go deeper on ChiCTR-IPR-16009493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009493.